Skip to main content
Erschienen in: Pituitary 3/2013

01.09.2013

Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence

verfasst von: Ruth Sánchez-Ortiga, Laura Sánchez-Tejada, Oscar Moreno-Perez, Pedro Riesgo, Maria Niveiro, Antonio M. Picó Alfonso

Erschienen in: Pituitary | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Some pituitary adenomas (PA) demonstrate aggressive behavior with local invasion and recurrences. Angiogenesis is regarded as an essential step in the formation of solid tumors. The aim of this study is to find out whether angiogenic factors may have information about the aggressiveness of PA that could be useful in determining the frequency of follow-up and whether adjuvant therapy is necessary. In this retrospective descriptive study, we evaluated vascular endothelial growth factors (VEGF) and VEGF receptor (KDR) mRNA expression by RT-PCR analysis on 46 human PA samples. Clinical data, histological subtype and radiologic characteristics were studied to determine the associations between the variables and the pre-operative behavior of the tumor. In addition, we monitored 12 patients without adjuvant post-operative therapies over 46 months after surgery, determining progression of tumor remnants and its association with these markers. VEGF expression correlates with KDR expression (r = 0.40, p = 0.006). VEGF demonstrates different expression between histological subtypes (p = 0.036). The extension at magnetic resonance imaging showed that VEGF expression was related to suprasellar extension (p = 0.007), being expressed more on tumors with extrasellar growth than intrasellar ones (p = 0.008). Our results demonstrate a 27.5 times increased risk of extrasellar growth when VEGF expression exceeds 0.222 normalized copy number (NCN) (p = 0.002). Likewise, tumors with KDR greater than 0.750 NCN had less recurrence-free survival time (p = 0.032). Our results suggest that the expression of VEGF and its receptor could be a marker for poor outcome after partial tumor resection. These data should be considered in future studies evaluating angiogenic factors as therapeutic targets in patients with PA.
Literatur
1.
Zurück zum Zitat Turner HE, Harris AL, Melmed S, Wass JA (2003) Angiogenesis in endocrine tumors. Endocr Rev 24(5):600–632CrossRefPubMed Turner HE, Harris AL, Melmed S, Wass JA (2003) Angiogenesis in endocrine tumors. Endocr Rev 24(5):600–632CrossRefPubMed
2.
Zurück zum Zitat Kurosaki M, Saeger W, Abe T, Ludecke DK (2008) Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res. doi:10.1179/174313208X289499 PubMed Kurosaki M, Saeger W, Abe T, Ludecke DK (2008) Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res. doi:10.​1179/​174313208X289499​ PubMed
3.
Zurück zum Zitat McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87(9):4238–4244CrossRefPubMed McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87(9):4238–4244CrossRefPubMed
5.
Zurück zum Zitat Raica M, Coculescu M, Cimpean AM, Ribatti D (2010) Endocrine gland derived-VEGF is down-regulated in human pituitary adenoma. Anticancer Res 30(10):3981–3986PubMed Raica M, Coculescu M, Cimpean AM, Ribatti D (2010) Endocrine gland derived-VEGF is down-regulated in human pituitary adenoma. Anticancer Res 30(10):3981–3986PubMed
7.
Zurück zum Zitat Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA (2000) Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85(3):1159–1162CrossRefPubMed Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA (2000) Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85(3):1159–1162CrossRefPubMed
8.
Zurück zum Zitat Kerbel RS, Viloria-Petit A, Okada F, Rak J (1998) Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4(5):286–295PubMed Kerbel RS, Viloria-Petit A, Okada F, Rak J (1998) Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4(5):286–295PubMed
9.
Zurück zum Zitat Ferrara N (2000) Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15–35 (discussion 35–16)PubMed Ferrara N (2000) Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15–35 (discussion 35–16)PubMed
11.
Zurück zum Zitat Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161(2):851–858CrossRefPubMed Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161(2):851–858CrossRefPubMed
12.
Zurück zum Zitat Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M (1998) Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol 96(5):453–462CrossRefPubMed Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M (1998) Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol 96(5):453–462CrossRefPubMed
13.
Zurück zum Zitat Fukui S, Otani N, Nawashiro H, Yano A, Nomura N, Tokumaru AM, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Shima K, Ooigawa H (2003) The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma. J Clin Neurosci 10(3):320–324CrossRefPubMed Fukui S, Otani N, Nawashiro H, Yano A, Nomura N, Tokumaru AM, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Shima K, Ooigawa H (2003) The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma. J Clin Neurosci 10(3):320–324CrossRefPubMed
14.
Zurück zum Zitat Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM (2003) The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 148(2):203–211CrossRefPubMed Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM (2003) The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 148(2):203–211CrossRefPubMed
15.
Zurück zum Zitat Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I, Genovesi M, Martino E (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26(1):23–28PubMed Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I, Genovesi M, Martino E (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26(1):23–28PubMed
16.
Zurück zum Zitat Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L (1999) Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10(3):229–235CrossRefPubMed Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L (1999) Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10(3):229–235CrossRefPubMed
17.
Zurück zum Zitat Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O’Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC (1998) Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4(12):3017–3024PubMed Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O’Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC (1998) Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4(12):3017–3024PubMed
18.
Zurück zum Zitat Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969PubMed Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969PubMed
19.
Zurück zum Zitat Borg SA, Kerry KE, Royds JA, Battersby RD, Jones TH (2005) Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells. Eur J Endocrinol 152(2):293–300. doi:10.1530/eje.1.01843 CrossRefPubMed Borg SA, Kerry KE, Royds JA, Battersby RD, Jones TH (2005) Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells. Eur J Endocrinol 152(2):293–300. doi:10.​1530/​eje.​1.​01843 CrossRefPubMed
21.
Zurück zum Zitat Iuchi T, Saeki N, Osato K, Yamaura A (2000) Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142(12):1345–1351CrossRef Iuchi T, Saeki N, Osato K, Yamaura A (2000) Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142(12):1345–1351CrossRef
22.
Zurück zum Zitat Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U (2006) Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol 191(1):249–261CrossRefPubMed Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U (2006) Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol 191(1):249–261CrossRefPubMed
24.
Zurück zum Zitat Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B, Ince N (2010) Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior? Neuro Endocrinol Lett 31(6):823–828PubMed Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B, Ince N (2010) Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior? Neuro Endocrinol Lett 31(6):823–828PubMed
25.
Zurück zum Zitat Lawnicka H, Pisarek H, Kunert-Radek J, Pawlikowski M (2008) Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro. Neuro Endocrinol Lett 29(1):113–116PubMed Lawnicka H, Pisarek H, Kunert-Radek J, Pawlikowski M (2008) Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro. Neuro Endocrinol Lett 29(1):113–116PubMed
26.
Zurück zum Zitat Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14(1):91–102CrossRefPubMed Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14(1):91–102CrossRefPubMed
27.
Zurück zum Zitat Taboada GF, Luque R, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65–74CrossRefPubMed Taboada GF, Luque R, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65–74CrossRefPubMed
Metadaten
Titel
Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence
verfasst von
Ruth Sánchez-Ortiga
Laura Sánchez-Tejada
Oscar Moreno-Perez
Pedro Riesgo
Maria Niveiro
Antonio M. Picó Alfonso
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2013
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-012-0434-4

Weitere Artikel der Ausgabe 3/2013

Pituitary 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.